The literature reported several novel applications of PET-imaging agents in PCa: one was combining a PSMA-targeted imaging agent with a second imaging agent for the more precise staging of PCa; another was using a pair of radioisotopes for both the imaging and therapy (theranostic) with PSMA-targeted molecules. Here, FOLH1 is linked to posterior cortical atrophy.